Observational studyBMC pharmacology & toxicology2023

Analysis of the relation between adverse events and overall survival in patients treated with pembrolizumab as a first-line treatment for metastatic NSCLC.

Lisa Faoro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.